MX2017006476A - Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos. - Google Patents

Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.

Info

Publication number
MX2017006476A
MX2017006476A MX2017006476A MX2017006476A MX2017006476A MX 2017006476 A MX2017006476 A MX 2017006476A MX 2017006476 A MX2017006476 A MX 2017006476A MX 2017006476 A MX2017006476 A MX 2017006476A MX 2017006476 A MX2017006476 A MX 2017006476A
Authority
MX
Mexico
Prior art keywords
microorganisms
effective against
novel
components
derivatives
Prior art date
Application number
MX2017006476A
Other languages
English (en)
Inventor
Lee Pace John
Edwin WILES Marc
Michelle Adams Stacy
HUSSEY Elizabeth
Original Assignee
Fleurir Abx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fleurir Abx Llc filed Critical Fleurir Abx Llc
Publication of MX2017006476A publication Critical patent/MX2017006476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones antimicrobianas novedosas que comprenden por lo menos una forma de una fosfomicina (o análogos adecuados, o derivados de los mismos), y por lo menos una sulfonamida (o análogos adecuados, o derivados de los mismos), y/o por lo menos una diaminopiridina (o análogos adecuados, o derivados de los mismos). Las composiciones antimicrobianas generalmente incluyen dos o más de los componentes como una combinación novedosa, proporcionada en una sola combinación o formulación, o proporcionada independientemente con exposiciones sobrepuestas de los dos o más componentes. Estas composiciones novedosas, cuando se proporcionan como los dos o más componentes, son efectivas contra microorganismos susceptibles, y son efectivas contra microorganismos resistentes a fármacos susceptibles (por ejemplo, bacterias, parásitos), que incluyen bacterias resistentes de multi-fármacos. Estas composiciones novedosas también son efectivas contra microorganismos o cepas de los mismos ahora susceptibles a la combinación aunque los microorganismos o cepas de los mismos se encontraron previamente o se consideraron resistentes o intolerantes a por lo menos uno de los componentes de la composición novedosa, cuando el por lo menos un componente se utilizó solo en lo que se consideró una cantidad de dosificación o concentración efectiva.
MX2017006476A 2014-11-18 2015-11-18 Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos. MX2017006476A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462081394P 2014-11-18 2014-11-18
US201562104805P 2015-01-18 2015-01-18
US201562245095P 2015-10-22 2015-10-22
PCT/US2015/061324 WO2016081592A1 (en) 2014-11-18 2015-11-18 Combination therapy effective against microorganisms, including drug resistant microorganisms

Publications (1)

Publication Number Publication Date
MX2017006476A true MX2017006476A (es) 2017-09-12

Family

ID=56014503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006476A MX2017006476A (es) 2014-11-18 2015-11-18 Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.

Country Status (6)

Country Link
US (1) US10898501B2 (es)
EP (1) EP3220920A4 (es)
CA (1) CA2968135A1 (es)
MX (1) MX2017006476A (es)
TW (1) TWI725948B (es)
WO (1) WO2016081592A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345717B2 (en) * 2013-09-25 2016-05-24 Zavante Therapeutics, Inc. Method for improving drug treatments in mammals
US10898501B2 (en) 2014-11-18 2021-01-26 Fleurir Abx, Llc Combination therapy effective against microorganisms, including drug resistant microorganisms
US11925653B2 (en) * 2021-01-25 2024-03-12 Fleurir Abx, Llc Combination therapy effective against microorganisms, including drug resistant microorganisms
US20230398101A1 (en) * 2022-06-09 2023-12-14 Fleurir Abx Llc Co-agents as Therapy Against Anaerobic Pathogens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815321A2 (pt) 2007-08-31 2015-02-10 Statens Seruminstitut "composição, plataforma, kit uso de uma composição, método de diagnóstico, método de manufatura da composição, método de manufatura da plataforma, método de manufatura do kit"
US10898501B2 (en) 2014-11-18 2021-01-26 Fleurir Abx, Llc Combination therapy effective against microorganisms, including drug resistant microorganisms

Also Published As

Publication number Publication date
WO2016081592A1 (en) 2016-05-26
EP3220920A1 (en) 2017-09-27
TW201632177A (zh) 2016-09-16
US20180369259A1 (en) 2018-12-27
CA2968135A1 (en) 2016-05-26
US10898501B2 (en) 2021-01-26
TWI725948B (zh) 2021-05-01
EP3220920A4 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
CA2956871C (en) Compounds active towards bromodomains
AU2015247815A8 (en) Ion channel activators and methods of use
EP3165227A4 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017001379A (es) Producto antiseptico, proceso para prepararlo y su uso.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
BR112016006048A8 (pt) composições antimicrobianas
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
TW201613864A (en) Novel compounds
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
MX2017006476A (es) Terapia de combinacion efectiva contra microorganismos, que incluye microorganismos resistentes a farmacos.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
EA201692493A8 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
HRP20190381T1 (hr) Herbicidni pripravci koji sadrže izoksaflutol i diflufenikan kao jedine herbicidno aktivne sastojke
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
BR112018016095A2 (pt) formulação de fragrância, método para aperfeiçoar, melhorar ou modificar uma formulação de fragrância, e, produto de fragrância.
UA116677C2 (uk) Спосіб боротьби зі шкідливими рослинами та синергічна гербіцидна композиція